Drugs / PRV-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04690426 | Dec 2020 → Dec 2021 | coxsackievirus infectious disease | Provention Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRV-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04690426 ↗ |
| Modality | Vaccine | “a multivalent, formalin-inactivated vaccine including CVB serotypes 1-5 (PRV-101)” PMID 38369573 ↗ Feb 2024 |
| Route | Intramuscular | “given by intramuscular injections at weeks 0, 4 and 8” PMID 38369573 ↗ Feb 2024 |